| canakinumab versus placebo | |||
| CANTOS, 2017 NCT01327846 | Quarterly Subcutaneous Canakinumab 50mg, 150mg, 300mg for 36 months versus placebo | Stable Post-myocardial Infarction Patients With Elevated hsCRP | double-blind Follow-up duration: 36 months |
| dabigatran versus placebo | |||
| REDEEM, 2009 NCT00621855 | dabigatran 4 dosages (50mg twice daily, 75mg twice daily, 110mg twice daily, 150mg twice daily) versus placebo | patients with recent acute coronary syndromes (ST- or non-ST-elevation myocardical infarction) | double blind Follow-up duration: 6 months |
| succinobucol versus placebo | |||
| ARISE, 2007 NCT00066898 | succinobucol (300 mg/day) versus placebo | high-risk patients with recent acute coronary syndrome | Double blind Follow-up duration: 24 months mean canada, US, UK, South Africa |
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
